|1.||Louis, Elan D: 14 articles (09/2014 - 08/2007)|
|2.||Zheng, Wei: 13 articles (09/2014 - 08/2007)|
|3.||Jiang, Wendy: 11 articles (09/2014 - 03/2008)|
|4.||Factor-Litvak, Pam: 11 articles (09/2014 - 01/2008)|
|5.||Guchhait, Nikhil: 5 articles (12/2013 - 09/2011)|
|6.||Gerbin, Marina: 5 articles (01/2013 - 12/2010)|
|7.||Nasehi, Mohammad: 4 articles (11/2013 - 05/2010)|
|8.||Paul, Bijan Kumar: 4 articles (08/2012 - 09/2011)|
|9.||Rios, Eileen: 4 articles (09/2008 - 01/2008)|
|10.||Pellegrino, Kathryn M: 4 articles (09/2008 - 01/2008)|
12/01/2003 - "Therefore, harmane seems to be protective against grand mal seizures in the MES model but not against a petit mal seizure model (PTZ) in mice."
12/01/2003 - "The study investigated the activity of harmane on maximal electroshock seizures (MES) and seizures induced by pentilentetrazole (PTZ) in mice. "
12/01/2003 - "The convulsions produced by PTZ were decreased by the low dose of harmane (2.5 mg/kg), but the high dose of harmane (10 mg/kg) resulted in worse grade V convulsions followed by more lethality compared with PTZ alone. "
12/01/2003 - "Harmane (2.5, 5.0, or 10 mg/kg intraperitoneally) increased the threshold of seizures in MES dose-dependently. "
10/01/1982 - "In mice, convulsion-producing doses of caffeine (120 mg/kg intravenously) and harmane (30 mg/kg intravenously) lowered the specific binding of 3H-FZ in vivo by 12-31%. "
09/15/2008 - "These links between cancer and ET and between high blood harmane and cancer in ET deserve further study."
08/16/2012 - "The present work demonstrates the photophysical characterization of the interaction of a promising cancer cell photosensitizer, harmane (HM), with biomimetic micellar nanocavities having varying surface charge characteristics. "
09/15/2008 - "Log blood harmane concentration was highest in ET cases with cancer when compared with other groups (P = 0.009). "
09/15/2008 - "Log blood harmane concentration was higher in ET cases vs. controls (P = 0.02) and in participants with vs. without cancer (P = 0.02). "
09/15/2008 - "Using a case-control design, we compared the prevalence of cancer in ET cases vs. controls, and determined whether blood harmane concentrations are elevated among ET cases with cancer. "
|3.||Amnesia (Dissociative Amnesia)
11/27/2013 - "In the present study, effects of the histaminergic system of the dorsal hippocampus (CA1) on harmane-induced amnesia were examined. "
11/27/2013 - "Suggesting a possible role of CA1 histaminergic system in harmane-induced amnesia."
08/01/2012 - "Involvement of the cholinergic system of CA1 on harmane-induced amnesia in the step-down passive avoidance test."
05/25/2010 - "In the present study, effects of dopamine D1 and D2 receptor antagonists on the harmane (HA)-induced amnesia and exploratory behaviors were examined in mice. "
05/25/2010 - "Involvement of dopamine D1/D2 receptors on harmane-induced amnesia in the step-down passive avoidance test."
|4.||Hepatocellular Carcinoma (Hepatoma)
11/15/2010 - "In the present study, we examined the ability of harman to induce AhR-mediated signal transduction in human and rat hepatoma cells; HepG2 and H4IIE cells. "
07/01/2004 - "In two cell lines, the rat hepatoma cell line H4IIE and the human breast cancer cell line MCF-7, we investigated 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeAC), 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) and Harman representing the different classes of HA at concentrations from 10(-8) to 10(-4) M. "
|5.||Chromosome Aberrations (Chromosome Abnormalities)
12/01/2001 - "Genotoxic effects of the alkaloids harman and harmine assessed by comet assay and chromosome aberration test in mammalian cells in vitro."
09/01/1992 - "Glu-P-2, IQ, MeIQ, harman, and harmine did not induce chromosome aberrations by themselves at the concentrations used in this study. "
09/01/1992 - "A alpha C, MeA alpha C, Glu-P-1, Glu-P-2, IQ, MeIQ, harman and harmine increased chromosome aberrations only in the presence of S9 mix. "
|2.||DNA (Deoxyribonucleic Acid)
|8.||2- amino- 3,4- dimethylimidazo(4,5- f)quinoline (MeIQ)